(firstQuint)Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy.

 Patients were randomly assigned to the nafamostat mesilate (NM) group or the no anticoagulant (NA) group.

 In patients assigned to the NM group, NM (20mg/h) was used for maintenance anticoagulation.

 Whereas, in patients assigned to the NA group, normal saline (2mL/h) was infused for continuous renal replacement therapy.

.

 Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy@highlight

Randomized study to evaluate the efficacy and safety of nafamostat mesilate use during continuous renal replacement therapy in acute kidney injury patients at a high risk of bleeding.

